Characterization of Patient-Reported Outcomes in Moderate to Severe Psoriasis

Abstract

Background: The Patient Benefit Index (PBI) is a recently developed instrument to assess patient satisfaction with treatment. It has been applied to only a limited number of psoriasis patients. Objective: Characterization of patient-reported outcomes (PRO) in patients with moderate to severe psoriasis Methods: 1,787 patients with plaque psoriasis were documented. Psoriasis Area and Severity Index (PASI), body surface area (BSA), Dermatology Life Quality Index (DLQI) and PBI were determined. Correlations were calculated and the persistence of PBI improvement and strength of treatment effect were evaluated. A regression analysis was performed to characterize predictors of PBI and DLQI improvements. Results: Significant correlations exist between ΔPASI/ΔBSA and ΔDLQI. Also, DLQI and PBI are correlated. Improvement in the skin condition has a positive and sustainable impact on all need dimensions of the PBI. The best early predictor for PBI was PASI 75 at treatment week 8, relevant factors predicting quality of life were PBI/subscale 4, (reducing physical impairment), ΔBSA and ΔPASI. Conclusion: Improvement in skin condition correlates with improvements in quality of life in patients with plaque psoriasis. Successful treatment leads to significant and sustainable patient benefit. While PBI subscale 4 is a good predictor for quality of life, more work is necessary to identify potential predictors for patient benefit.

Pictorial representation of illness and self measure (PRISM): an effective tool to assess the burden of psoriasis

“…However, missing information on disease severity regarding the investigated population makes it difficult to compare both results. Even so, this observation has been detected in several studies, which found negligible or missing association between higher PASI scores and DLQI or HRQoL in general . A possible explanation may be that patients with higher impact of psoriasis have higher variance in answering their PRO′s, e.g.…”

Psoriasis Comorbidities: Results from the National Psoriasis Foundation Surveys 2003 to 2011

“…Patient-reported outcomes elicit evaluations of disease severity and quality of life directly from patients, and they are an integral part of outcome assessment [7]. Traditional patient-reported outcomes seek the perspectives of the patients in disease severity and quality of life and have been validated in various clinical and research settings [8].…”

“…Traditional patient-reported outcomes seek the perspectives of the patients in disease severity and quality of life and have been validated in various clinical and research settings [8]. Newer patient-reported outcome measures even consider personal therapeutic goals by accounting for individual preferences [7]. In this study, the NPF surveys asked patients to directly assess BSA involvement and categorize disease severity based on these BSA measurements.…”

Handbook of Psoriasis and Psoriatic Arthritis

“…Despite this, not all countries have their own treatment guidelines. Although the European S3 guidelines in psoriasis [74] can help to fill the gap in these countries, they cannot reflect local policies and practices. For this reason, clinicians often rate national guidelines more highly than European guidelines.…”

“…The overall benefit from treatment -indexed as 'Patient benefit index' is highly predictive for QoL, patient satisfaction, and patient reported benefits from treatment [73]. It is also more predictive for the overall patient benefit than clinical outcomes such as delta PASI or delta BSA [74].…”